v3.26.1
Revenue
 12 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue 25. REVENUE

Revenue is disaggregated as follows:

 

 

Years ended

 

 

 

March 31,

 

 

March 31,

 

 

March 31,

 

 

 

2026

 

 

2025

 

 

2024

 

Cannabis

 

 

 

 

 

 

 

 

 

Canadian adult-use cannabis1

 

$

94,472

 

 

$

78,828

 

 

$

92,803

 

Canadian medical cannabis2

 

 

90,818

 

 

 

77,032

 

 

 

66,362

 

International markets cannabis

 

 

28,654

 

 

 

30,866

 

 

 

32,518

 

 

 

$

213,944

 

 

$

186,726

 

 

$

191,683

 

 

 

 

 

 

 

 

 

 

 

Storz & Bickel

 

$

70,659

 

 

$

82,269

 

 

$

79,464

 

This Works

 

 

-

 

 

 

-

 

 

 

21,256

 

Other1,2

 

 

-

 

 

 

-

 

 

 

4,743

 

Net revenue

 

$

284,603

 

 

$

268,995

 

 

$

297,146

 

1 A reclassification of $433 of ancillary cannabis revenues from Other to Canadian adult-use cannabis occurred for the year ended March 31, 2024.

2 A reclassification of $5,016 of ancillary cannabis revenues from Other to Canadian medical cannabis occurred for the year ended March 31, 2024.

3 Canadian adult-use cannabis net revenue during the year ended March 31, 2026 reflects excise taxes of $51,856 (year ended March 31, 2025 - $36,442; and year ended March 31, 2024 - $40,115).

4 Canadian medical cannabis net revenue during the year ended March 31, 2026 reflects excise taxes of $10,368 (year ended March 31, 2025 - $8,532; and year ended March 31, 2024 - $6,673).

The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $5,107 for the year ended March 31, 2026 (year ended March 31, 2025 – $4,266; and year ended March 31, 2024 – $4,159). As of March 31, 2026, the liability for estimated returns and price adjustments was $3,638 (March 31, 2025 – $2,661).